BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong SJ, Krugliak Cleveland N, Akiyama S, Zullow S, Yi Y, Shaffer SR, Malter LB, Axelrad JE, Chang S, Hudesman DP, Rubin DT. Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States. Crohn's & Colitis 360 2021;3:otab002. [DOI: 10.1093/crocol/otab002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 . Ustekinumab. Reactions Weekly 2022;1925:497-497. [DOI: 10.1007/s40278-022-24274-z] [Reference Citation Analysis]
2 Honap S, Al-hillawi L, Baillie S, Bancil A, Matini L, Lau R, Kok KB, Patel K, Walsh A, Irving PM, Samaan MA. Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102168] [Reference Citation Analysis]
3 Aoki Y, Sujino T, Kawaguchi T, Sugimoto S, Shimada F, Yoshimatsu Y, Kiyohara H, Nanki K, Mikami Y, Takabayashi K, Hosoe N, Ogata H, Iwao Y, Kanai T. Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otac010] [Reference Citation Analysis]